Emerging Therapeutic Approaches to Engage the Androgen Receptor for the Treatment of Castration-Resistant Prostate...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Castration-resistant prostate cancer (CRPC) presents a significant clinical challenge, with tumors often progressing despite androgen receptor (AR)-targeted therapies.
• Androgen receptor (AR) signaling remains a key driver of tumor growth in CRPC, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review next-generation therapies targeting the AR signaling axis in CRPC.
• To highlight agents in preclinical or clinical development that disrupt AR function through direct and indirect mechanisms.

Main Methods:

• Review of preclinical and clinical data on novel agents targeting AR signaling in CRPC.
• Analysis of mechanisms of action, including direct AR degradation, targeting novel AR domains, and indirect modulation of AR co-regulators and transcriptional machinery.

Main Results:

• Emerging therapies include novel agents that degrade AR or target non-conventional domains, aiming to overcome resistance to existing anti-androgens.
• Indirect strategies focus on modulating AR-associated proteins, chromatin accessibility, and splicing factors to inhibit AR-driven gene expression.

Conclusions:

• These next-generation therapies offer promising strategies to more effectively suppress AR activity in CRPC.
• The development of these agents has the potential to reshape future treatment paradigms for CRPC.